Trust the original IL-17 inhibitor with the most in-market experience1-3*†
*First IL-17A antagonist approved by the FDA in 2015.1-3
†Across rheumatology and dermatology.
‡Studied in patients since 2007.4 FDA approved for moderate to severe PsO in adults in 2015, for active PsA and AS in adults in 2016, for active nr-axSpA with objective signs of inflammation in adults in 2020, for moderate to severe PsO in children 6 years and older, active PsA in children 2 years and older, and active ERA in children 4 years and older in 2021, and for moderate to severe HS in adults in 2023.8
§Data based on April 2025 NSOB. Indication split based on the competitive view. “Total” indication volume is as-reported volume; would be higher than the sum of individual indications.5
||As of December 2024; SC prescriptions across all indications.6
¶Based on number of patients studied in completed clinical trials with IL-17 antagonists, IL-23 antagonists, and IL-12/23 antagonists.7
Definitions
AS, ankylosing spondylitis; ERA, enthesitis-related arthritis; FDA, US Food and Drug Administration; HS, hidradenitis suppurativa; IL, interleukin; nr-axSpA, non-radiographic axial spondyloarthritis; NSOB, National Source of Business; PsA, psoriatic arthritis; PsO, plaque psoriasis; SC, subcutaneous.
References
1. Cosentyx. Prescribing information. Novartis Pharmaceuticals Corp.
2. Taltz. Prescribing information. Eli Lilly & Co.
3. Siliq. Prescribing information. Bausch Health US LLC.
4. Data on file. AIN457A2102 Clinical Study Report. Novartis Pharmaceuticals Corp; December 2008.
5. Data on file. Weekly PsO + HS NBRx. Novartis Pharmaceuticals Corp; April 2025.
6. Data on file. Cosentyx Patient Count and TRx. Novartis Pharmaceuticals Corp; December 2024.
7. Data on file. Summary of Approved IL Antagonist Trials. Novartis Pharmaceuticals Corp; March 2025.
8. Cosentyx FDA approval history. Drugs.com. Accessed February 26, 2025. https://drugs.com/history/cosentyx.html